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ABSTRACT
Objective: To determine the prevalence of interstitial cys-
titis and endometriosis in patients with chronic pelvic
pain.
Methods: A prospective analysis was conducted in 178
women with CPP who presented with bladder base/ante-
rior vaginal wall and/or uterine tenderness, with or with-
out irritative voiding symptoms. The Potassium Sensitivity
Test was used to assess bladder epithelial dysfunction.
Patients were evaluated with concurrent laparoscopy and
cystoscopy with hydrodistention.
Results: Laparoscopic findings among the 178 patients
with chronic pelvic pain supported a diagnosis of endo-
metriosis in 134 (75%) patients, and cystoscopy confirmed
a diagnosis of interstitial cystitis in 159 (89%) patients.
Both interstitial cystitis and endometriosis were diagnosed
in 115 patients (65%). The Potassium Sensitivity Test was
positive in 146 (82%) patients, with 140 (96%) of these
patients diagnosed with interstitial cystitis and 105 (72%)
with endometriosis.
Conclusions: Results of this prospective study show that
interstitial cystitis and endometriosis may frequently co-
exist in patients with chronic pelvic pain. A positive Po-
tassium Sensitivity Test accurately predicted the presence
of interstitial cystitis in 96% of these patients with chronic
pelvic pain, as confirmed by cystoscopic hydrodistention.
It is necessary to consider the diagnosis of endometriosis
and interstitial cystitis concurrently in the evaluation of
patients with chronic pelvic pain to avoid unnecessary
delay in identifying either condition.
Key Words: Interstitial cystitis, Endometriosis, Chronic
pelvic pain.
INTRODUCTION
Chronic pelvic pain (CPP) is estimated to affect more than
9 million women in the United States.1 Up to 40% of
laparoscopies and 10% to 12% of all hysterectomies are
performed for CPP.2,3 In addition to lost productivity and
decreased quality of life, the diagnosis and treatment of
CPP consumes nearly $3 billion of health care expendi-
tures annually.1
The management of CPP is challenging due to the numer-
ous possible differential diagnoses and contributing fac-
tors associated with this condition. Possible differential
diagnoses include endometriosis, endosalpingiosis, pelvic
adhesions, ovarian remnant syndrome, interstitial cystitis
(IC), adenomyosis, and uterine leiomyomatas.4–7 These
conditions may present with similar symptoms, and one
or more may exist concomitantly in a given patient.8
Endometriosis is one of the more prevalent gynecologic
diagnoses among women with CPP, affecting more than
half of those patients who receive a diagnosis for their
CPP.1,2,5,6,9–11 Symptoms include dyspareunia, cyclic peri-
menstrual low abdominal pelvic pain, symptom flares
after sexual intimacy, and irritative voiding in the case of
urinary tract involvement.12 A definitive diagnosis of en-
dometriosis requires visual confirmation of the lesion dur-
ing laparoscopy, and histologic confirmation of the pres-
ence of both ectopic endometrial glands and stroma.12
Interstitial cystitis, or pelvic pain of bladder origin, is
another disorder that may be associated with CPP.8 The
cause of IC is unclear, but it is thought to be multifactorial
and progressive, involving bladder epithelial dysfunction,
mast cell activation, and bladder sensory nerve upregula-
tion (Figure 1).13–15 Estimates of the prevalence of IC in
the United States range from 10 to 510/100 000 cases.16,17
Recent evidence suggests that this condition may, in fact,
be much more prevalent than current estimates.14,18
The symptoms of IC include urinary urgency/frequency
and/or pelvic pain in the absence of urinary tract infec-
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SCIENTIFIC PAPERtion. Patients may also report dyspareunia and/or cyclic
pain in association with the menses.14,19 Some patients
may present with only urologic symptoms; conversely,
15% of patients present with chronic pain and no urologic
symptoms.14 Patients with early IC may have only 1 or 2
symptoms, whereas at later stages, the full spectrum of
symptoms may emerge and bladder capacity may be re-
duced.20 Recent data suggest that outcomes may be im-
proved when IC is detected and treated at earlier stages.
The Potassium Sensitivity Test (PST) was developed by
Parsons et al14,15,21 to indicate abnormal permeability of
the bladder epithelium, which is thought to play a central
role in the pathophysiology of IC. Use of the PST has been
validated in a number of studies,18,19,22,23 and may be used
to help confirm the diagnosis of IC, particularly at earlier
stages of the disease.
In a previously published retrospective review,9 we diag-
nosed biopsy-confirmed active endometriosis in 81% of
patients with IC who had undergone concurrent laparos-
copy and cystoscopy with hydrodistention in evaluation
for CPP. Those findings suggested that these 2 conditions
often exist concomitantly, and that the diagnosis of one
condition should not preclude evaluation for the other.
The objective of this study was to incorporate the use of
the PST along with cystoscopy/hydrodistention and lapa-
roscopy to prospectively determine the prevalence of IC
and endometriosis in patients with CPP.
METHODS
This prospective evaluation included 178 women aged 18
to 60 years who presented from October 2000 to Novem-
ber 2002 at the Midwest Regional Center for Chronic
Pelvic Pain and Bladder Control. Subjects were selected
for this study based on the presence of abdominal/pelvic,
uterine, uterine sacral, and bladder/anterior vaginal wall
tenderness during a physical examination. Symptoms of
CPP had persisted for more than 6 months and included
dyspareunia, dysmenorrhea, and low abdominal pelvic
pain with or without irritative voiding symptoms, such as
urinary frequency, urgency, nocturia, hesitancy, and sen-
sation of incomplete emptying. Laboratory studies in-
cluded a urinalysis, urine cytology, and urine and genital
cultures. In addition, mycoplasma and urealyticum cul-
tures were performed from the vaginal fornix. Negative
culture results, including those for cytology, were re-
quired for enrollment.
All patients were tested for bladder potassium sensitivity
using the PST as previously described by Parsons et al,21,22
and all patients underwent concurrent laparoscopic, cys-
toscopic, and bladder hydrodistention evaluations. A di-
agnosis of endometriosis was confirmed by biopsy and
treated by surgical excision. The criteria used for a diag-
nosis of endometriosis included the pathologist-con-
firmed presence of ectopic glands and stroma.
Cystoscopy and hydrodistention were performed either
before or after the laparoscopic evaluation. Bladder hy-
drodistention was conducted using sterile water with
80cm to 100cm of passive hydrostatic pressure being ap-
plied. The bladder was distended for a minimum of 2
minutes, and then the water was slowly drained. The
submucosal petechial hemorrhages, or glomerulations,
were observed as the bladder emptied, or during a second
filling of the bladder. The diagnosis of IC was based on
the National Institutes of Health–National Institute of Di-
abetes and Digestive and Kidney Diseases (NIH-NIDDK)
guidelines, including the presence of 10 glomerulations
per quadrant in 3 of the 4 quadrants of the bladder cavity
and the presence of terminal hematuria.24
RESULTS
Presenting Symptoms
All patients in this study presented with both bladder base
and uterine tenderness on physical examination. Overall,
145 (81%) of the 178 study subjects with CPP had irritative
urinary symptoms suggestive of overactive bladder.
Results of Cystoscopy with Hydrodistention and
Laparoscopy
Diagnosis and PST results for patients in this study are
shown in Figure 2. Of the 178 patients evaluated, 159
(89%) exhibited cystoscopic findings of IC, 134 (75%) had
Figure 1. Proposed cycle of etiology of interstitial cystitis.
14
Adapted from Evans RJ. Treatment approaches for interstitial
cystitis: multimodality therapy. Rev Urol. 2002;4(suppl 1):S16–
S20.
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tion, and 115 (65%) were diagnosed with both conditions.
In addition, 19 (11%) patients had endometriosis with no
diagnosis of IC, and 44 (25%) had confirmed IC without
endometriosis. The 159 patients with IC met the NIH-
NIDDK guidelines for IC with the presence of glomerula-
tions and hematuria. The diagnosis of IC was confirmed
by experienced urologists who were involved in clinical
research for treatment of IC.
Results of Potassium Sensitivity
Testing–Relationship With Cystoscopic Results
Among the total study population of 178 patients, a pos-
itive PST was found in 146 (82%) patients. Of these 146
patients, 114 (78%) had irritative voiding symptoms. In
addition, cystoscopic evidence of IC was found in 140
(96%) patients and, based on laparoscopic findings, en-
dometriosis was demonstrated in 105 (72%).
In the original subgroup of 159 patients with cystoscopic
evidence of IC, 140 (88%) showed increased potassium
sensitivity based on the PST, and 129 (81%) had urologic
symptoms of urinary urgency and frequency. Cystoscopic
evidence of IC was found in 19 (12%) patients who had a
negative PST, and 15 of those patients presented with
irritative voiding symptoms.
DISCUSSION
In this study, we have shown that endometriosis and IC
often exist concomitantly in patients with CPP who
present with uterine and bladder tenderness. Among the
134 patients with endometriosis, 86% were also diagnosed
with IC. Conversely, among the 159 patients with IC, 72%
were also found to have endometriosis. We have therefore
prospectively confirmed our earlier published results that
IC and endometriosis have a high rate of overlap in this
group of patients. As the patients in this study were se-
lected for both uterine and bladder tenderness, the rate of
overlap between gynecologic and urologic diagnoses is
likely to be higher than in the general population of
patients with CPP. However, these results emphasize the
need for a careful physical examination and symptom
history in patients with CPP, and the need to perform
concurrent cystoscopy with hydrodistention and laparos-
copy. If cystoscopy had been performed only in patients
with irritative voiding symptoms/overactive bladder, a di-
agnosis of IC would have been missed in approximately
20% of patients.
Other studies have also found that IC is frequently diag-
nosed in patients with CPP, and that it overlaps to a high
degree with other diagnoses. In one study25 of 45 patients
from general gynecologic practices who were scheduled
to undergo laparoscopy for CPP, 17 (38%) were found to
have IC based on the presence of irritative voiding symp-
toms and positive cystoscopic findings. In that study, 7
(41%) women diagnosed with IC also had endometriosis.
Endometriosis was also diagnosed in 14 (50%) women
who did not have IC. Notably, 30 (67%) of the women in
that study had clinical symptoms of urgency and fre-
quency or nocturia, and 10 women who were IC-negative
had at least 10 glomerulations per quadrant noted in only
2 quadrants of the bladder. These results suggest that
some women may have had early IC that did not meet the
stringent NIDDK criteria for a diagnosis of IC.25
A questionnaire-based study evaluated the prevalence of
concomitant disease in individuals with diagnosed IC.26 In
this study in which patients with IC were not selected for
CPP or gynecologic symptoms, the prevalence of endo-
metriosis was approximately 17%. By comparison, the
prevalence of endometriosis in the general population is
estimated to be 1% to 7%.12 In this survey, patients with IC
were also found to be substantially more likely than the
general population to have various autoimmune disor-
ders, such as inflammatory bowel disease (100-fold
greater risk) and systemic lupus erythematosus (30- to
50-fold greater risk), although these conditions were still
relatively rare compared with other concomitant illnesses.
The cause of both IC and endometriosis is thought to
include an immune component, suggesting a possible
pathophysiologic basis for the increased risk of one con-
dition with the other.26
Figure 2. Diagnosis and PST results for patients in this study.
CPPchronic pelvic pain; EMendometriosis; ICinterstitial
cystitis; PSTPotassium Sensitivity Test. *Glomerulations and
hematuria according to the National Institutes of Health–
National Institute of Diabetes and Digestive and Kidney Diseases
guidelines. †Presence of pathologist-confirmed presence of ec-
topic gland stroma.
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good at detecting the presence of IC: 96% (140) of patients
with a positive PST had cystoscopic findings compatible
with IC. Only 3.4% (6) of patients with a positive PST were
cystoscopically negative. Previous studies have also re-
ported that the rate of false positives is very low with the
PST.22,23,27–29 These results indicate that a positive PST
may be sufficient to indicate a diagnosis of IC.22 However,
in our study, 12% (19) of women with cystoscopically
confirmed IC had a negative PST, suggesting that, in the
case of a negative PST, cystoscopy should still be per-
formed.
Simple conservative methods are available for treating IC,
including diet, pelvic floor physical therapy, and medica-
tions like hydroxyzine and pentosan polysulfate sodium
(Elmiron
®, Ortho-McNeil Pharmaceutical, Inc, Raritan,
NJ). Recent published articles have indicated the efficacy
of oral contraceptives in treating IC and CPP.30,31 Many
thought-leaders believe that the treatment of women with
CPP has often been ineffective because the underlying
cause is actually urologic rather than gynecologic.32
Therefore, it is reasonable to conclude that ineffective
management of CPP and treatment failures may be the
result of missed diagnoses of IC.
CONCLUSION
This study demonstrates that patients with CPP may have
IC, endometriosis, or both conditions concomitantly. It is
therefore imperative to evaluate the patient for both con-
ditions, even when the diagnosis of one has been con-
firmed. When possible, cystoscopy with hydrodistention
should be performed concurrently with laparoscopy to
eliminate the need for a second procedure with the pa-
tient under general anesthesia and to facilitate the rapid
detection and treatment of IC. A positive PST may be
considered sufficient to diagnose IC and to begin treat-
ment. A negative PST is not sufficient to rule out the
presence of IC and should be followed up with cystos-
copy. In the evaluation of the female with CPP, consider-
ation should be given to the bladder as a source of pain
early in the diagnostic workup.
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